Moderna: Five-Year Cancer Data Say Wall Street Is Still Pricing the Wrong Variable

Moderna: Five-Year Cancer Data Say Wall Street Is Still Pricing the Wrong Variable

In an ironic way, the strongest clinical data Moderna has ever produced only makes the market's framing of the stock look older. The five-year follow-up from the Phase 2b KEYNOTE-942 study, released jointly with Merck, showed that intismeran autogene — the personalized mRNA cancer vaccine the two companies built together — combined with the immunotherapy KEYTRUDA reduced the risk of high-risk melanoma returning or causing death by 49% versus KEYTRUDA alone. A hazard ratio of 0.510 means a patient's risk of recurrence or death at any point in time fell by about half, and the whole 95% confidence band (0.294 to 0.887) sits under 1.0, so this is not a result carried by a few outlier patients. AInvest's aggregate rating signal still labels Moderna (NASDAQ: MRNA) a Hold, even as AInvest's fundamental score for the company sits at 7.87. Between a five-year efficacy readout this clean and a rating signal that cautious sits the disconnect that makes this stock an argument.

Five years is the milestone that matters in adjuvant care — treatment given after surgery to lower the risk of relapse — because most recurrences happen in the first five years from diagnosis. The 49% figure at five years holds at virtually the same magnitude as the benefit seen at three years, which is the durability read clinicians care about: the benefit is not leaking away as patients carry it forward. For a cancer therapy, that is the difference between a delay and what surgeons treat as close to a cure signal.

The market's bear case leans on a single event: the FDA declined to fast-track the medicine through an accelerated-approval path off the earlier three-year data and told the companies to complete a Phase 3 first. Read that for what it is — a process gate, not a verdict on efficacy. The Phase 2b enrolled only 157 patients; that is not a registration-standard dataset, and the nominal statistics attached to the five-year result (one-sided p = 0.0075) are exactly what the FDA wants replaced with confirmatory data. The registration study in melanoma, INTerpath-001, is fully enrolled, and INTerpath-001 results are expected later this year.

1. The market is pricing the wrong variable. Wall Street's Hold is calibrated to a liquidated COVID franchise: 2025 revenue landed near $1.9 billion, second-quarter 2026 sales were just $145 million at the seasonal trough, and there is no forward EPS today to hang a multiple on. An 11x trailing-sales price looks like a growth premium, but that frame is meaningless on a revenue base that collapsed for one product-specific reason. The variable that actually drives the equity is the probability-weighted oncology franchise, and five years of durable efficacy data just moved that probability up.

2. The trough is a product cycle, not a model failure. The COVID collapse and the culling of clinical programs in CMV, herpes, and shingles look to Wall Street like a dying platform. Management responded the way a fixable model responds: annual operating expenses were cut by roughly $2 billion and R&D dollars were redirected toward oncology and rare disease. That is a capital-deployment fix, not a broken business model — and the Marlborough, Massachusetts facility is on track for commercial launch manufacturing of the cancer vaccine.

3. It is funded to the catalyst. Moderna told investors it ended 2025 with roughly $8 billion of cash and investments, guided GAAP operating expenses down to about $4.9 billion for 2026, and targets cash breakeven in 2028. Trailing free cash flow is still negative — about $1.24 billion over the past four quarters — but the burn narrowed roughly 64% year over year. The company does not need the capital markets to survive to its own 2028 plan; it needs clinical wins, and the first confirmatory one is due this year.

   

4. Merck is the validation, and Merck is already believed. Merck (NYSE: MRK) co-developed the program and brings the commercial muscle; Merck's aggregate rating signal is Buy, and the stock trades near its 52-week high at roughly 17.5x forward earnings with a 2.5% dividend yield. The same data were announced for both companies, yet the Street holds one and buys the other. That contrast is the whole misunderstanding in miniature. For Merck the collaboration extends its flagship immuno-oncology franchise into a fresh cycle; for Moderna it is the platform's first proof of life. Moderna's oncology leadership framed the readout as evidence of "mRNA's potential in cancer care" — the oldest knock against the company is that its platform only ever made a vaccine for a virus, and this is the counter.

5. The cost of admission is the readout, and the readout is the re-rating trigger. A 113% year-to-date run has already closed the panic gap from the $22 low — the easy part of this move is gone. What remains is the Phase 3 result. A positive INTerpath-001 confirmation would put the first-ever registration-trial data behind a personalized neoantigen vaccine — each dose manufactured to a patient's own tumor signature — and industry projections put an approved melanoma product at multibillion-dollar annual sales. Against a roughly $20.6 billion enterprise value, with around $8 billion of that balance sheet in cash, that is a large slice of the company currently being priced as a COVID throwback. The program keeps expanding while the market looks the other way, and the companies have since added a third Phase 3 trial in earlier-stage lung cancer. A negative or delayed readout, by contrast, resets the story to a stock that needs to find a bottom again.

The whole company — a commercial vaccine franchise, a late-stage rare-disease pipeline, and an eight-trial oncology program — sits around $20.6 billion in enterprise value. The five-year data likely increased the odds that INTerpath-001 confirms the Phase 2b benefit, and the market's Hold rating does not yet reflect what a confirmatory readout could be worth in billions of annual sales. The standoff has a clean break condition: the melanoma Phase 3 result, expected later this year. Until it lands, the stock is a catalyst trade priced on the wrong variable; the data say the odds of that catalyst coming through have never been better.